Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 112 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neuroma Clear all
Terminated Phase 2Phase 3 Interventional

Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

NCT05130866
View directory record Official record
Conditions
Neurofibromatosis Type 2
Interventions
REC-2282, Placebo
Drug
Lead sponsor
Recursion Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
14
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Jul 22, 2026, 8:26 AM EDT
Completed Phase 2 Interventional Results available

Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560

NCT04351373
View directory record Official record
Conditions
Vestibular Schwannoma
Interventions
Fluorescein Sodium, YELLOW560 filter
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Jul 22, 2026, 8:26 AM EDT
Recruiting Early Phase 1 Interventional

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

NCT07493447
View directory record Official record
Conditions
Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer, Pituitary Adenoma
Interventions
Panitumumab-IRDye800
Drug
Lead sponsor
Eben Rosenthal
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 22, 2026, 8:26 AM EDT
Completed No phase listed Observational

Subtotal Resection of Large Acoustic Neuromas With Possible Stereotactic Radiation Therapy

NCT01129687
View directory record Official record
Conditions
Neuroma, Acoustic
Interventions
Microsurgery, Stereotactic radiation therapy
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
9
States / cities
Stanford, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Jul 22, 2026, 8:26 AM EDT
Terminated Not applicable Interventional Results available

A Comparative Post-marketing Study of Commercially Available Peripheral Nerve Gap Repair Options

NCT00948025
View directory record Official record
Conditions
Traumatic Nerve Injury
Interventions
Hollow tube nerve conduit, synthetic or biosynthetic, Processed Human Nerve Tissue
Device · Other
Lead sponsor
Axogen Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Lexington, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Jul 22, 2026, 8:26 AM EDT
Terminated Early Phase 1 Interventional Results available

Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma

NCT02282917
View directory record Official record
Conditions
Vestibular Schwannoma, Meningioma, Acoustic Neuroma, Neurofibromatosis Type 2
Interventions
AR-42
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
4
States / cities
Stanford, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Jul 22, 2026, 8:26 AM EDT
Terminated No phase listed Observational

Surgical Treatment of Chronic Neuropathic Pain

NCT04287075
View directory record Official record
Conditions
Chronic Neuropathic Pain
Interventions
Surgical Management of Neuroma
Procedure
Lead sponsor
Axogen Corporation
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Tampa, Florida • Indianapolis, Indiana • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Jul 22, 2026, 8:26 AM EDT
Recruiting Not applicable Interventional

Short-term Implanted Electrodes Following Regenerative Peripheral Nerve Surgery for Improving Prosthetic Limb Control Signals

NCT03260400
View directory record Official record
Conditions
Amputation Neuroma, Amputation
Interventions
a bipolar percutaneous intramuscular electromyography electrode
Device
Lead sponsor
University of Michigan
Other
Eligibility
22 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Jul 22, 2026, 8:26 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors

NCT03095248
View directory record Official record
Conditions
Neurofibromatosis 2, Vestibular Schwannoma, Meningioma, Ependymoma, Glioma
Interventions
Selumetinib
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Jul 22, 2026, 8:26 AM EDT
Recruiting Phase 2 Interventional

Pain Outcomes After Digital Amputation Using Tulavi Allay™ Nerve Cap

NCT06915662
View directory record Official record
Conditions
Neuroma, Neuropathic Pain
Interventions
Tulavi allay Nerve Cap
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
22 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jul 22, 2026, 8:26 AM EDT
Completed Phase 2 Interventional

ALGRX 4975 in the Treatment of Patients With Morton's Neuroma

NCT00130962
View directory record Official record
Conditions
Neuroma
Interventions
ALGRX 4975
Drug
Lead sponsor
AlgoRx Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Owings Mills, Maryland • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 2, 2005 · Synced Jul 22, 2026, 8:26 AM EDT
Suspended Phase 1 Interventional

Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma

NCT01083966
View directory record Official record
Conditions
Vestibular Schwannoma
Interventions
Bevacizumab (Avastin)
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 22, 2026, 8:26 AM EDT
Recruiting Not applicable Interventional

Surgical Treatments for Postamputation Pain

NCT05009394
View directory record Official record
Conditions
Residual Limb Pain, Amputation Neuroma, Phantom Limb Pain, Pain, Neuropathic, Pain, Nerve
Interventions
Targeted Muscle Reinnervation (TMR), Regenerative Peripheral Nerve Interface (RPNI), Standard neuroma treatment, neuroma excision, and muscle burying
Procedure
Lead sponsor
Prometei Pain Rehabilitation Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Jul 22, 2026, 8:26 AM EDT
Not listed Not applicable Interventional

Intraoperative Electrically-evoked ABRs in Patients Undergoing Vestibular Schwannoma Surgery

NCT05248113
View directory record Official record
Conditions
Deafness
Interventions
Electrical stimulation of cochlear nerve
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Jul 22, 2026, 8:26 AM EDT
Active, not recruiting Not applicable Interventional

Tolerability and Feasibility Pilot Clinical Study of a Large-Diameter Nerve Cap for Protecting and Preserving Terminated Nerve Ends

NCT04865679
View directory record Official record
Conditions
Symptomatic Neuroma, Amputation, Chronic Nerve Pain
Interventions
Axoguard Nerve Cap®
Device
Lead sponsor
Axogen Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 22, 2026, 8:26 AM EDT
Withdrawn Phase 4 Interventional

Evaluation of Neuroma Perfusion with Indocyanine Green Fluorescence Angiography

NCT06164392
View directory record Official record
Conditions
Neuroma, Neuroma Amputation, Neuroma of Upper Limb, Neuroma of Lower Limb
Interventions
Indocyanine green
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Jul 22, 2026, 8:26 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2

NCT01419639
View directory record Official record
Conditions
Neurofibromatosis Type II
Interventions
Everolimus (RAD001) , Afinitor®
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
3 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Jul 22, 2026, 8:26 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)

NCT02283957
View directory record Official record
Conditions
Painful Intermetatarsal Neuroma (Morton's Neuroma)
Interventions
CNTX-4975, Placebo
Drug · Other
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
16
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Castro Valley, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Jul 22, 2026, 8:26 AM EDT
Withdrawn Phase 2 Interventional

Botulinum Toxin Type A for Neuroma Pain

NCT01374191
View directory record Official record
Conditions
Neuroma
Interventions
onabotulinum toxin type-A, placebo, 2nd phase - onabotulinum toxin type-A
Drug · Other
Lead sponsor
Southern Illinois University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Jul 22, 2026, 8:26 AM EDT
Completed Not applicable Interventional

Simultaneous Cochlear Implantation During Translabyrinthine Resection of Vestibular Schwannoma

NCT03958006
View directory record Official record
Conditions
Vestibular Schwannoma, Cochlear Implantation
Interventions
Cochlear implant
Device
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 99 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Jul 22, 2026, 8:26 AM EDT
Recruiting Phase 1Phase 2 Interventional

Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma

NCT06517888
View directory record Official record
Conditions
Vestibular Schwannoma
Interventions
AAVAnc80-antiVEGF via Akouos Delivery Device
Combination Product
Lead sponsor
Akouos, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
Baltimore, Maryland • Rochester, Minnesota • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 22, 2026, 8:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Neurologic Examination of Wide and Narrow Tourniquets

NCT02023476
View directory record Official record
Conditions
Nerve Compression
Interventions
MRI
Radiation
Lead sponsor
Medical University of Vienna
Other
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Jul 22, 2026, 8:26 AM EDT
Completed Not applicable Interventional Results available

Postoperative Peripheral Nerve Stimulation for Management of Post-amputation Pain

NCT03484429
View directory record Official record
Conditions
Phantom Limb Pain, Postoperative Pain, Neuroma, Acute Pain, Chronic Pain, Residual Limbs, Amputation
Interventions
Peripheral nerve stimulation, Standard Medical Therapy
Device · Other
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Jul 22, 2026, 8:26 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma

NCT04196933
View directory record Official record
Conditions
Migraine, Vestibular Migraine, Vestibular Schwannoma, Motion Sickness, Dizziness, Vestibular Disorder
Interventions
Temporal Binding Adaptation - PSS training, Temporal Binding Adaptation - PSS adaptation with VI stimulation, Chronic Motion-modulated Stimulation
Behavioral
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
8 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Jul 22, 2026, 8:26 AM EDT